NCT06863090Recruiting
In Vivo Dosimetry for Brachytherapy Study
A Single-centre Feasibility Study Investigating the Use of in Vivo Dosimetry in Patients Receiving High Dose Rate (HDR) Brachytherapy for Gynaecological and Prostate Cancers
Source: ClinicalTrials.gov · Last updated 11 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The main study aim is the investigate the clinical use of in vivo dosimeters (small measurement devices) for brachytherapy (internal radiotherapy).
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 20 (estimated)
- First submitted
- 3 Mar 2025
- Start date
- Mar 2025
- Primary completion date
- Mar 2026
- Lead sponsor
- East and North Hertfordshire NHS Trust
- Diseases
- Prostate cancer
- NCT number
- NCT06863090
What you commit to
- Study type: Observational
- Planned participants: 20
- From Mar 2025 to the primary completion date, Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous brachytherapy exposure to the treatment site
- Patients with the following medical conditions: coagulopathies, history of another primary malignancy, known allergy or sensitivity to study materials; previous or current fistulae
Other
- Patients unable to give informed consent
- Patients unable to have a regional or general anaesthetic
- Not able to understand the implications of participating in the study in English
- Patients with recent (within the last 6 months) or currently participating in interventional research
Who the study is looking for
- Patients aged 18 years and above
- Patients receiving HDR brachytherapy using iridium-192 (192Ir) radioactive source either as a monotherapy or in combination with external beam radiotherapy for:
- histologically/radiologically proven primary or locally recurrent prostate cancer
- locally advanced gynaecological malignancy in the primary and recurrent setting
- primary cervix carcinoma (squamous, adenocarcinoma, adenosquamous) FIGO IB2-IVA
- primary vulval FIGO I-IVA
- primary vaginal FIGO I-IVA
- primary endometrial cancer FIGO Stage I-IVA (not suitable for surgery)
- endometrial cancer receiving adjuvant vaginal vault brachytherapy
- recurrent cervix, vulval, vaginal or endometrial cancer suitable for brachytherapy as discussed in a regional gynae-oncology multidisciplinary meeting.
- World Health Organisation (WHO) or Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mount Vernon Cancer Centre Coordinator of this site? Confirm its status | Northwood | United Kingdom | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.